Compare Indonesia Energy Corporation Limited (INDO) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Indonesia Energy Corporation Limited vs Merck & Co., Inc. — how do they compare? Indonesia Energy Corporation Limited trades at $3.01 (market cap $46.01M), while Merck & Co., Inc. trades at $125.52 (market cap $307.25B). The key difference: Merck & Co., Inc. is far larger — about 6677.9× Indonesia Energy Corporation Limited's market cap, and Merck & Co., Inc. pays a 2.73% dividend while Indonesia Energy Corporation Limited pays none. Which is the better fit depends on your goals.
| INDO | MRK | |
|---|---|---|
Market Cap | $46.01M | $307.25B |
Sector | Energy | Health |
52-Week High | $6.74 | $129.52 |
52-Week Low | $2.49 | $77.60 |
Enterprise Value | $41.38M | $350.66B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INDO trades at $2.99, down 1.32% today, with a bullish technical signal from moving averages and oscillators. The company shows negative profitability metrics including -253.4% net income margin but maintains 100% analyst buy ratings. Recent operational milestones include commencement of drilling at the Kruh Block, providing potential catalysts for future revenue growth.
While current financials show significant losses, analyst optimism and recent operational progress suggest turnaround potential. Key risks include execution challenges in oil exploration and sustained negative cash flow. The stock presents speculative opportunity for investors betting on successful well development and future profitability improvement.
Merck (MRK) trades at $125.44, down 1.62% on the day, with a neutral technical signal. The company reported strong 2025 results with revenue of $65.01B and net income of $18.25B, though Q1 2026 saw a loss. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, with institutional investors increasing positions. Valuation ratios include a P/E of 35.04 and ROE of 18.97%, indicating solid profitability but premium pricing.
Outlook remains positive with a consensus price target of $137.30, reflecting 9.5% upside potential. Risks include rising debt levels and competitive pressures in pharma. Analyst sentiment is bullish with 68% buy ratings, supporting a favorable investment case amid ongoing strategic acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Indonesia Energy Corporation Limited
Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
